What Is THCV (Tetrahydrocannabivarin)? The Molecule, the Research and Its Legal Status

You may have heard of THCV through a nickname like "diet weed," or in a news story about weight or blood sugar. It is completely natural to be curious: What is this molecule, how is it different from THC, and what does research actually show? In this article we explain in plain language the chemistry of THCV, how it acts in the body, what human studies have found and its legal status in Turkey. We do not cover plant strains or products.

What is THCV?

THCV is one of the hundreds of compounds found in the cannabis plant (Cannabis sativa) and belongs to the cannabinoid family (we introduce the family in our article on cannabinoids). Its name is very similar to THC (tetrahydrocannabinol), the best-known cannabinoid, because the two molecules have almost the same skeleton.

The difference is small but important: THC has a five-carbon side chain at one end, while in THCV this chain has three carbons. The "-varin" ending refers to this shorter chain; the same family also includes other "varin" cannabinoids such as CBDV (cannabidivarin). The molecular formula of THCV is C₁₉H₂₆O₂, and that of THC is C₂₁H₃₀O₂.

Like other cannabinoids, THCV first forms in the plant in its acid form (THCVA); it turns into THCV when the plant is heated or dried and stored. In most cannabis plants it is found in much smaller amounts than THC and CBD.

How does it act in the body?

Our body has a signaling system that helps regulate many functions, from appetite to mood: the endocannabinoid system (more in this article). The two best-known "locks" of this system are the CB1 and CB2 receptors. CB1 is found mostly in the brain, and CB2 mostly in immune cells.

• THC activates the CB1 receptor. The high and the increase in appetite largely come from this effect.
• THCV, by contrast, in laboratory studies bound to CB1 and blocked the effect of substances that activate it, instead of activating it. In animals, this blocking effect was seen at low doses, while at higher doses an activating effect on CB1 was seen. It partly activated the CB2 receptor (Pertwee 2008).

An important reason for scientists' interest in THCV is this: there was a medicine called rimonabant that blocked CB1 and was developed for weight loss, but it was withdrawn because of psychiatric side effects such as depression. Rimonabant also suppressed the receptor's own natural activity. THCV, on the other hand, is thought to be a "neutral" blocker that only blocks stimulation coming from outside (Tudge 2015; Wargent 2013). Whether this difference would lead to a safer outcome in humans is not yet known.

Does THCV cause a high?

At the doses used in human studies, THCV has not been seen to cause a high or mental fog. In a study of ten healthy men, participants who took 10 mg of THCV every day for five days (study dose; not a personal recommendation) could not tell THCV apart from an inactive pill (placebo) (Englund 2016). Because THCV is known to be able to activate CB1 at higher doses in animals, however, the effect of high doses in humans is not well known. Claims such as "it never gets you high" or "it gives you energy" are not backed by human studies.

What does the research say?

Most of what we know about THCV comes from laboratory and animal studies. Human studies are few, small and mostly short. The important ones are:

Blood sugar and type 2 diabetes

The most important human study in this area was done in 62 people with type 2 diabetes who were not using insulin. Participants were randomly assigned to five groups: CBD alone, THCV alone, two different CBD-THCV mixtures, or placebo, so each group had about 12 people. In the group taking 5 mg of THCV twice a day (study dose; not a personal recommendation), fasting blood sugar fell compared with placebo after 13 weeks, and a measure of how well insulin-producing cells work improved. The study's main outcome, "good cholesterol" (HDL), did not change. There was no clear difference between those taking CBD alone and those taking placebo, and the mixtures did not change the results (Jadoon 2016).

This is promising, but it is a single, small pilot study; its results have not been repeated in larger studies. In a study in mice, THCV also improved blood sugar balance and insulin sensitivity; interestingly, it did not clearly change food intake or weight gain (Wargent 2013). We look at the role of CBD in diabetes separately in our diabetes and metabolism guide.

Weight and appetite

THCV's "diet weed" nickname arose mainly from animal studies and laboratory findings; human studies are limited. The most direct human data on appetite come from a brain imaging study in which 20 healthy volunteers were given a single 10 mg dose of THCV: THCV increased the brain's response to rewarding images such as chocolate and to unpleasant ones such as moldy strawberries, but how much participants liked or wanted these foods did not change (Tudge 2015).

In a weight loss study, 44 people used mouth-dissolving strips containing THCV and CBD, or a placebo, for 90 days. Reductions in weight and waist size were reported in the THCV-CBD groups compared with placebo (Smith 2025). However, the study was carried out by a single author who is affiliated with a company; 44 of the 56 people who started completed the study, and the high-dose and placebo groups had only ten people each. That is why the results need to be confirmed by independent, larger studies. We discuss weight and CBD in our article Can CBD help with weight loss?.

Together with THC

In the ten-person study mentioned earlier, participants who had taken THCV for five days were then given a small amount of THC into a vein. THCV reduced the rise in heart rate caused by THC and the impairment on a memory test; nine of the ten participants felt the effect of THC more weakly. On the other hand, THCV increased some memory errors. The authors stress that the sample was small and the results should be interpreted with caution (Englund 2016).

Parkinson's and other areas

In animal models of Parkinson's disease, THCV was reported to have protective effects on nerve cells and to reduce involuntary movements caused by levodopa treatment (Espadas 2020). These findings come only from mice; it has not been tested in humans. There are no well-designed human studies of THCV in areas such as anxiety, focus or pain; there is not yet enough research on these topics, and studies are ongoing.

Possible side effects and safety

In small human studies, THCV was generally well tolerated; no serious side effects were reported (Jadoon 2016; Englund 2016). However, these studies involved few people and lasted a few months at most. There is not enough research on the safety of long-term use, the effect of high doses, or THCV's interactions with other medicines. Because it is thought to be able to affect blood sugar, it is especially important for people taking diabetes medicines to talk with their doctor about this.

THCV, THC and CBD compared

We explain the difference between THC and CBD in detail in our article on THC vs. CBD.

Legal status

Turkey: THCV was brought under Law No. 2313, the Uyuşturucu Maddelerin Murakabesi Hakkında Kanun (Law on the Control of Narcotic Substances), by Presidential Decree No. 10129, published in the Official Gazette on July 30, 2025. The list annexed to the decree includes both the form found in cannabis (Δ9-THCV) and Δ8-THCV by their chemical names (Presidential Decree 10129). Decrees of this kind determine which substances fall under this law (Law No. 2313, Art. 19). The Turkish Penal Code covers the manufacture and trade of narcotics in Article 188, and buying, possessing or using them for personal use in Article 191.

The Ministry of Health's Kenevirden Elde Edilen Ürünlere Dair Yönetmelik (Regulation on Products Derived from Hemp) of January 31, 2026 defines "cannabinoid" as the general name for plant cannabinoids obtained naturally from cannabis and gives THC, CBD, CBN and CBG as examples; it does not mention THCV separately. In supplement and personal care products, THC can be at most 0.3%, and cannabinoids must be present at levels that do not cause a narcotic effect. We did not find an official statement on whether a cannabis product containing THCV could be licensed under this regulation.

Cannabis-derived products, including CBD, can be sold only in pharmacies and only with a license (Law No. 7557, regulation of January 31, 2026). Products sold online, on social media or in stores are outside this channel. Those classed as medicines and health products are dispensed with a prescription; no prescription requirement is stated for supplement products with a THC content of at most 0.3%. As of October 2026, there is no approved (licensed) CBD medicine in Turkey. Growing cannabis without a permit is also prohibited in Turkey. Details: Regulation guide.

Other countries: The rules vary from country to country. In the United Kingdom, for example, THCV is considered a Class B controlled substance, like THC (UK Home Office). THCV is not listed by name in the UN's 1971 Convention on Psychotropic Substances (INCB Green List 2025); Turkey added THCV to its list by its own decision.

If you are thinking about using a product containing CBD or THCV

You can talk with your doctor about the following:

• What research shows for your situation, and that the data on THCV are still very limited,
• The medicines you take, especially diabetes medicines (see drug interactions),
• Whether the product contains THC and whether it is licensed.

Do not stop the treatment you use for diabetes or weight on your own; THCV is not a substitute for these treatments.

Conclusion

THCV is an interesting cannabinoid that is very similar to THC but interacts with receptors differently. Although the early results on blood sugar and weight are striking, they rest on a few small studies; today it is too early to say "it works." Scientists are continuing to look for answers to these questions with larger, independent studies.

Frequently asked questions

References